BIO-Europe Spring® 2016: RMI says it has USD 200 million already under management

Print 20 June 2016
EBD Group

Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. Gorbachev says the RMI fund was created in March 2012 by RUSNANO, the nanotechnology investment, research and development arm of the Russian government together with Domain Associates, a US life sciences technology venture investment firm. The ten-year closed end fund has USD 200 million under management and 17 separate investments so far spanning a wide range of biopharma and medtech companies and numerous collaborations with venture capitalists.

Source

Return